Amylin, Lilly, and Alkermes Await FDA Decision on Byetta for Diabetes

On February 25th, 2010, Amylin, Lilly, and Alkermes announced in a press release that the FDA had set March 12th 2010 as the Prescription Drug User Fee Act (PDUFA) action date for Byetta’s long acting formulation –  exenatide once weekly.   Our readers will recall that Byetta is used by type 2 diabetics for glycemic (blood glucose) control and [...]

BioHorizon Health Technology Surveillance Update: February 8, 2010

The BioHorizon Health Technology Surveillance Update gives readers a concise,  high level overview of the most important emerging health technology developments on a ongoing basis  including key FDA approvals, substantive clinical trial results and upcoming events of importance. First of all, on behalf of  the entire BioHorizon staff, let me welcome you to the BioHorizon Health [...]